You are here

Article Text

Article menu
Download PDFPDF
Review Articles
Proteomics in cancer research
  1. W. Wu*,
  2. W. Hu† and
  3. J. J. Kavanagh†
  1. * Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
  2. † Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: Weiguo Wu, MD, Ph.D, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030–4009, e-mail: weiguowu{at}mdanderson.org and John J. Kavanagh, MD, Professor, Department of Gynecoligical Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 401, Houston, TX 77030–4009, e-mail:jkavanag{at}mdanderson.org.

Abstract

With the human genome sequence now determined, the field of molecular medicine is moving beyond genomics to proteomics. In the field of cancer research, the key question is: how can oncologists best use techniques of proteomics in basic research and clinical application? In the postgenomic era, proteomics promises the discovery of biomarkers and tumor markers for early detection and diagnosis, novel protein-based drug targets for anticancer therapy, and new endpoints for the assessment of therapeutic efficacy and toxicity. This review paper will explore key themes in proteomics and their application in clinical cancer research.

  • proteomics
  • clinical application
  • cancer

http://dx.doi.org/10.1136/ijgc-00009577-200209000-00001

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.